VivekAnandUpadhyayMD

PubMed

• 1 citations
  Real-World Analysis of Off-Label Use of Molecularly Targeted Therapy in a Large Academic Medical Center Cohort.
  Vivek A Upadhyay, Bruce E Johnson, Adam B Landman, Michael J Hassett> ;JCO Precision Oncology. 2022 Jan 1
• 8 citations
  Genomic Profiling of Combined Hepatocellular Cholangiocarcinoma Reveals Genomics Similar to Either Hepatocellular Carcinoma or Cholangiocarcinoma
  Karthikeyan Murugesan, Radwa Sharaf, Meagan Montesion, Jay A. Moore, James Pao, Dean Pavlick, Garrett M. Frampton, Vivek A. Upadhyay, Brian M. Alexander, Vincent A. Mi...> ;JCO Precision Oncology. 2021 Aug 19
• 5 citations
  Landscape Analysis of Oncology Mobile Health Applications
  Vivek A. Upadhyay, Adam B. Landman, Michael J. Hassett> ;JCO Clinical Cancer Informatics. 2021 May 25
• 3 citations
  A Space-Time Continuum for Immunotherapy Biomarkers in Gastroesophageal Cancer?
  Samuel J. Klempner, Vivek A. Upadhyay, Joseph Chao> ;Clinical Cancer Research. 2020 Dec 15
• 16 citations
  Deaths and complications associated with the management of acute immune thrombotic thrombocytopenic purpura.
  Meaghan E. Colling, Lova Sun, Vivek A. Upadhyay, Justine H. Ryu, Ang Li, Lynne Uhl, Richard M. Kaufman, Christopher P. Stowell, Walter H. Dzik, Robert S. Makar, Pavan ...> ;Transfusion. 2020 Feb 21
• 54 citations
  Multicenter analysis of outcomes in blastic plasmacytoid dendritic cell neoplasm offers a pretargeted therapy benchmark
  Justin Taylor, Michael Haddadin, Vivek A. Upadhyay, Erwin Grussie, Neha Mehta-Shah, Andrew M. Brunner, Abner Louissaint, Scott B. Lovitch, Ahmet Dogan, Amir T. Fathi, ...> ;Blood. 2019 Aug 22
• 18 citations
  Utilizing a PLASMIC score‐based approach in the management of suspected immune thrombotic thrombocytopenic purpura: a cost minimization analysis within the Harvard TMA...
  Vivek A. Upadhyay, Benjamin P. Geisler, Lova Sun, Lynne Uhl, Richard M. Kaufman, Christopher P. Stowell, Robert S. Makar, Pavan K. Bendapudi> ;British Journal of Haematology. 2019 May 26
• 26 citations
  Predictors of relapse and efficacy of rituximab in immune thrombotic thrombocytopenic purpura
  Lova Sun, Johnathan P. Mack, Ang Li, Justine H. Ryu, Vivek A. Upadhyay, Lynne Uhl, Richard M. Kaufman, Christopher P. Stowell, Walter Sunny Dzik, Robert S. Makar, Pava...> ;Blood Advances. 2019 May 14
• 8 citations
  Induction chemotherapy in acute myeloid leukaemia: origins and emerging directions.
  Vivek A. Upadhyay, Amir T. Fathi> ;Current Opinion in Hematology. 2018 Mar 1
• 19 citations
  Isocitrate dehydrogenase (IDH) inhibition as treatment of myeloid malignancies: Progress and future directions
  Vivek A. Upadhyay, Andrew M. Brunner, Amir T. Fathi> ;Pharmacology & Therapeutics. 2017 Sep 1
• 21 citations
  Clinical Scoring Systems in Thrombotic Microangiopathies.
  Pavan K. Bendapudi, Vivek A. Upadhyay, Lova Sun, Marisa B. Marques, Robert S. Makar> ;Seminars in Thrombosis and Hemostasis. 2017 Jun 8
• 273 citations
  Derivation and external validation of the PLASMIC score for rapid assessment of adults with thrombotic microangiopathies: a cohort study
  Pavan K. Bendapudi, Shelley Hurwitz, Ashley Fry, Marisa B. Marques, Stephen W. Waldo, Ang Li, Lova Sun, Vivek A. Upadhyay, Ayad Hamdan, Andrew M. Brunner, John M. Gans...> ;The Lancet. Haematology. 2017 Apr 1
• 5 citations
  The Approach to Acute Lymphoblastic Leukemia in Older Patients: Conventional Treatments and Emerging Therapies.
  Victor D. Fedorov, Vivek A. Upadhyay, Amir T. Fathi> ;Current Hematologic Malignancy Reports. 2016 Mar 3
• 23 citations
  Shedding LIGHT (TNFSF14) on the tumor microenvironment of colorectal cancer liver metastases
  Jian Zhong Qin, Vivek Upadhyay, Bellur S. Prabhakar, Ajay V. Maker> ;Journal of Translational Medicine. 2013 Mar 20
• Join now to see all